Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 5 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

2
Player Avatar cvdynasty3 (99.91) Submitted: 12/2/2009 9:49:36 AM : Underperform Start Price: $5.62 SNTS Score: +13.74

FDA will not approve... Inside info boys!!!

Will lose 20-25 pct easily, FDA will need more data

Featured Broker Partners


Advertisement